Bausch+Lomb Results Presentation Deck

Top 10 Revenues (Includes FX Impact) Rank Product/Franchises 1 2 3 4 LO 7 8 9 Ocuvite® + PreserVision® Surgical Consumables¹ SofLens Biotrue ONEday Biotrue® Solutions Franchise Ⓡ Surgical Implantables¹ Surgical Equipment¹ renu® LumifyⓇ 10 Bausch+Lomb ULTRA® BAUSCH + LOMB 2Q23 $104 M $102M $59M $49M $49M $47M $46M $43M $43M $42M 1Q23 $81M $95M $60M $52M $35M $44M $44M $42M $38M $51M FY22 $387M $359M $246M $201M $153M $188M $171M $176M $131M $177M 4Q22 $114M $94M $62M $50M $37M $49M $45M $47M $35M $43M 3Q22 $98M $85M $62M $53M $39M $45M $42M $44M $30M $46M 1. As of the first quarter of 2023, certain products were recategorized across the consumables, implantables and equipment product categories. This change was made as management believes this better aligns these products in their respective categories. Prior period presentations of product categories have been conformed to current product category structure to allow investors to evaluate results between periods on a consistent basis. 2Q22 $94M $93M $61M $49M $39M $49M $42M $43M $35M $44M 25

View entire presentation